JIB-04 Has Broad-Spectrum Antiviral Activity and Inhibits SARS-CoV-2 Replication and Coronavirus Pathogenesis
Abstract
The coronavirus disease 2019 (COVID-19), the disease caused by SARS-CoV-2 infection, is an ongoing public health disaster worldwide. Although several vaccines are available as a preventive measure and the FDA approval of an orally bioavailable drug is on the horizon, there remains a need for developing antivirals against SARS-CoV-2 that could work on the early course of infection.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 22, 2022
- Source ID
- 10.1128/mbio.03377-21
Entities
People
- Adam L Bailey
- Adrianus Boon
- Baochao Fan
- Beibei Niu
- Bin Li
- Elisabeth D. Martínez
- Gaopeng Hou
- Hinissan P. Kohio
- Houda H. Harastani
- James Brett Case
- Jian Xu
- Jinzhu Zhou
- Juhee Son
- Lu Chen
- María Florencia Gómez Castro
- Michael S. Diamond
- Paul W Rothlauf
- Pei-Yong Shi
- Qiru Zeng
- Rongli Guo
- Ruochen Zang
- Sean P J Whelan
- Shimeng Huang
- Siyuan Ding
- Steven L. Brody
- Tamarand L. Darling
- Traci L. Bricker
- Xin Wang
- Xinjian Chang
- Yongxiang Zhao
- Zhuoming Liu
Organizations
- Harvard Medical School
- National Institutes of Health
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Robert A. Welch Foundation
- University of Texas Medical Branch
- University of Texas Southwestern Medical Center
- Washington University School of Medicine
- Washington University in St. Louis